Goodwin advised TRICares, a medtech company specializing in the field of minimally invasive treatment of tricuspid regurgitation, in its $50 million Series D financing round.
The round was raised from a single, strategic investor.
TRiCares is developing a transcatheter-based tricuspid valve replacement system aimed at addressing the need for a better treatment for this frequent and severe disease, while also avoiding open heart surgery. The proceeds from this financing will primarily be used to support the company through upcoming US and EU clinical milestones for its transfemoral tricuspid heart valve replacement system, Topaz.
The Goodwin team included:
- In Paris, Anne-Charlotte Rivière, Sonia Sassi and Augustin Piqueras on corporate aspects, and Charles-Henri de Gouvion Saint-Cyr on tax aspects;
- In London, Graham Defries on corporate aspects;
- In Boston, Mitchell Bloom on corporate aspects.